Advertisement

Topics

Fondation Ipsen Company Profile

06:33 EST 19th February 2019 | BioPortfolio

Established in 1983 under the aegis of the Fondation de France, the mission of the Fondation Ipsen is to contribute to the development and dissemination of scientific knowledge. The long-standing action of the Fondation Ipsen aims at fostering the interaction between researchers and clinical practitioners, which is indispensable due to the extreme specialisation of these professions. The ambition of the Fondation Ipsen is to initiate a reflection about the major scientific issues of the forthcoming years. It has developed an important international network of scientific experts who meet regularly at meetings known as Colloques Médecine et Recherche, dedicated to six main themes: Alzheimer's disease, neurosciences, longevity, endocrinology, the vascular system and cancer science. Moreover, in 2007, the Fondation Ipsen started three new series of meetings. The first series is an annual meeting organized in partnership with the Salk Institute and Nature and focuses on Biological Complexity; the second series is the “Emergence and Convergence” series with Nature, and the third with Cell and the Massachusetts General Hospital entitled “Exciting Biologies”. Since its beginning, the Fondation Ipsen has organised more than 100 international conferences, published 70 volumes with renowned publishers and 210 issues of a widely distributed bimonthly newsletter Alzheimer Actualités. It has also awarded more than 100 prizes and grants.


News Articles [86 Associated News Articles listed on BioPortfolio]

CohBar Founder Dr. Nir Barzilai Awarded the 2018 Fondation IPSEN Longevity Prize

MENLO PARK, Calif., Nov. 26, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related dise...

Raising Awareness about Early Onset Dementia: “Don’t Leave me now”, Written by Brian Daniels

Fondation IPSEN invites you to attend to a play about caring for people with early onset Alzheimer’s or cerebral dementia A free event open to everyoneNovember 21st, ...

L'innovateur Walid Al Banna Remporte la Saison 10 de Stars of Science de la Fondation du Qatar

DOHA, Qatar, November 24, 2018 /PRNewswire/ -- L'émission phare de la Fondation du Qatar appelle les talents scientifiques arabes à postuler pour participer à la Read more...

Ipsen to present new data from its oncology portfolio at the 2018 European Society for Medical ...

For further information :IpsenMediaIan Weatherhead, +44 (0) 1753 627733Vice President, Corporate External Communicationsian.weatherhead@ipsen.comorFanny Allaire, +33 (0) 1 58 33 ...

Ipsen appoints new general manager for the UK & Ireland

The French pharma company appointed a new general manager for its UK and Ireland office, Asad Mohsin Ali, who brings two decades of commercial experience and a bold vision for Ipsen’s global footpri...

Ipsen seeks candidates as it looks to spend over €1bn on pipeline growth

Ipsen is actively scouting candidates to boost its oncology, rare disease and neuroscience portfolio, said chief business officer Ivana Magovčević-Liebisch. The...Read More... The post Ipsen seeks ...

Exelixis and Ipsen start COSMIC-312 trial for advanced HCC

Exelixis and Ipsen have begun the Phase III COSMIC-312 trial of cabozantinib (cabometyx) in combination with atezolizumab (tecentriq) against sorafenib...Read More... The post Exelixis and Ipsen start...

With New HQ, Ipsen to Rapidly Expand North American Presence

With a patient-centric focus, Ipsen Biopharmaceuticals is on a mission to improve patients’ lives, leveraging its global reach and placing a strategic focus on external innovation.

Drugs and Medications [0 Results]

None

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Stability in GRN Inference.

Reconstructing a gene regulatory network from one or more sets of omics measurements has been a major task of computational biology in the last 20 years. Despite an overwhelming number of algorithms p...

Clinical Trials [9 Associated Clinical Trials listed on BioPortfolio]

Administration of GnRH Antagonist to Oocyte Donation Recipients

This prospective and randomized study was performed to evaluate whether the replacement of GnRH agonist by a GnRH antagonist in oocyte donation recipients during endometrial preparation h...

Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders

The purpose of this study is to compare ovulation induction using a flexible GnRH antagonist protocol and flare up GnRH agonist protocol in IVF patients with poor response to ovarian stimu...

Burden of Urinary Incontinence in Home Care Patients in the State of Geneva

Urinary incontinence (UI) is a frequent problem in community-dwelling older adults and has a huge burden on health complications and healthcare costs. Although effective treatments exist,...

Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients

The purpose of this study is to compare pregnancy rates and the occurrence of OHSS in PCOS patients who were treated with GnRH agonist and GnRH antagonist protocols ovarian stimulation dur...

Pharmaco-Economic Study of Cabozantinib in Renal Cell Carcinoma (RCC) Patients

In order to evaluate the cost-effectiveness (CE) of cabozantinib versus everolimus and axitinib for the adult aRCC patients who experienced the failure of prior VEGF-targeted therapy in Ta...

Companies [16 Associated Companies listed on BioPortfolio]

The Fondation IPSEN

Established in 1983 under the aegis of the Fondation de France, the ambition of the Fondation IPSEN is to initiate a reflection about the major scientific issues of the forthcomin...

Fondation Ipsen

Established in 1983 under the aegis of the Fondation de France, the mission of the Fondation Ipsen is to contribute to the development and dissemination of scientific knowledge. T...

Ipsen N.A.

Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2013. Ipsen’s ambition is to become a leader in specialty healthcare...

Ipsen S.A.

Ipsen is a global biopharmaceutical group, with sales exceeding 1 billion euros in 2009. The Group has total worldwide staff of more than 4,400 employees, of which nearly 900 cont...

Ipsen

Ipsen is a global biopharmaceutical group with total sales in excess of 1 billion euros in 2009, and total worldwide staff of more than 4,400. Its strategy is based on fast growin...

More Information about "Fondation Ipsen" on BioPortfolio

We have published hundreds of Fondation Ipsen news stories on BioPortfolio along with dozens of Fondation Ipsen Clinical Trials and PubMed Articles about Fondation Ipsen for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Fondation Ipsen Companies in our database. You can also find out about relevant Fondation Ipsen Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Psychiatry
Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...

Endocrinology
Diabetes Diabetes Endocrine Disorders Obesity Oxycontin Renal Disease Thyroid Disorders Endocrinology is the study of the endocrine glands and the hormones that they secrete (Oxford Medical Dictionary). There are several g...

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...


Corporate Database Quicklinks



Searches Linking to this Company Record